Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX208 in Adult LCH and ECD with BRAF V600E Mutation
NCT05092815Phase 2Unknown
- Sponsor
- Henlius
- Start
- Dec 2021
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HLX208 in Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD), sponsored by Henlius. Status: unknown.
02
Drugs
HLX208
03
Conditions
Langerhans cell histiocytosis (LCH)Erdheim-Chester disease (ECD)
Beyond the preview
Go deeper on NCT05092815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05092815.